Thus, treatment with a PTK7 neutralizing antibody increases the therapeutic efficacy of erlotinib, a small-molecule TKI effective for the treatment of metastatic and/or recurrent HNSCC, by downregulating β-catenin [94, 96]. This evidence concerns the gene PTK7 and head and neck squamous cell carcinoma.